KP104 for lupus-related blood vessel damage in kidneys
Part of Blood & lymphatic, Immune system & allergy, Skin clinical trials.
This Phase 2 trial tests KP104, a study medicine, to see if it is safe and tolerable and how it affects blood-related changes caused by lupus-related thrombotic microangiopathy. It may help people whose lupus is causing small blood vessel problems, especially involving blood and kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have lupus (SLE) confirmed based on standard 2019 criteria used by major rheumatology groups
- Your platelet count is low (below 150,000 per microliter)
- You have abnormal kidney function
- You have evidence of hemolytic anemia caused by small blood vessel damage (microangiopathic hemolytic anemia)
- You can give informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug, MK-1045, for people with lupus or rheumatoid arthritis. It aims to see if the drug is safe and how it affects your condition.
This early-phase trial tests a special immune cell therapy (UCAR T-cells) that targets two proteins (CD19 and BCMA) on the surface of lupus B cells. It is for people with difficult-to-treat lupus that affects the kidneys (lupus nephritis) who have not gotten better with standard treatments.
This trial tests a new treatment, UB-VV410, for people with active systemic lupus erythematosus (SLE) or lupus nephritis (kidney inflammation caused by lupus) that hasn't responded to standard treatments. It aims to see if this therapy can help control the disease.
This study tests a new therapy called NKX019, which uses specially engineered natural killer cells to target a protein on lupus cells. It is for people with moderate to severe lupus that has not responded to standard treatments, especially those with active kidney inflammation.
This study tests a new medicine called CHT105 for lupus patients whose kidney disease hasn't improved with standard treatments. The medicine targets specific immune cells that may be driving the kidney damage.
This Phase 2 study tests KP104 in people with IgA nephropathy (IgAN) or C3 glomerulopathy (C3G) to see if it improves kidney disease and is safe. It also tracks how the body handles the drug and how it affects disease markers in urine and blood.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.